Kymera Therapeutics (NASDAQ:KYMR) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.72) by 13.89 percent. This is a 34.74 percent increase over losses of $(0.95) per share from the same period last year. The company reported quarterly sales of $65.000 million which beat the analyst consensus estimate of $31.165 million by 108.57 percent. This is a 466.40 percent increase over sales of $11.476 million the same period last year.